Difference between revisions of "Entrectinib (Rozlytrek)"
Jump to navigation
Jump to search
m (Jwarner moved page Entrectinib (RXDX-101) to Entrectinib (Rozlytrek): FDA approval) |
m |
||
| Line 8: | Line 8: | ||
==Preliminary data== | ==Preliminary data== | ||
* '''Phase 1:''' Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017 Apr;7(4):400-409. Epub 2017 Feb 9. [http://cancerdiscovery.aacrjournals.org/content/7/4/400.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380583/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28183697 PubMed] | * '''Phase 1:''' Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017 Apr;7(4):400-409. Epub 2017 Feb 9. [http://cancerdiscovery.aacrjournals.org/content/7/4/400.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380583/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28183697 PubMed] | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Non-small cell lung cancer, ROS1-positive|ROS1+ NSCLC]] | ||
| + | *[[NTRK|Solid malignancies with NTRK fusions]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *8/15/2019: Granted accelerated approval for adults and pediatric patients 12 years of age and older with [[NTRK|solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation]], are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. | ||
| + | *8/15/2019: Approved for adults with metastatic [[Non-small cell lung cancer, ROS1-positive|non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive]]. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' RXDX-101 | *'''Code name:''' RXDX-101 | ||
| + | *'''Brand name:''' Rozlytrek | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| Line 20: | Line 30: | ||
[[Category:TRK inhibitors]] | [[Category:TRK inhibitors]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2019]] |
Revision as of 15:54, 19 August 2019
General information
Class/mechanism, from the NCI Drug Dictionary: An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Preliminary data
- Phase 1: Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017 Apr;7(4):400-409. Epub 2017 Feb 9. link to original article link to PMC article PubMed
Diseases for which it is used
History of changes in FDA indication
- 8/15/2019: Granted accelerated approval for adults and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.
- 8/15/2019: Approved for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
Also known as
- Code name: RXDX-101
- Brand name: Rozlytrek